Table 2.

Efficacy results in both treatment groups (per-protocol set).

	Study group (Growtropin-II) (n = 24)	Control group (Genotropin) (n = 28)	P value
ΔaHV at Wk 52 (cm/year)	5.28 ± 2.03	4.63 ± 6.19	.65 ± 2.12∗ [−0.53,1.83]†
Ht-SDS
Baseline	−2.70 ± 0.83	-2.62 ± 0.64	.8472
Wk 26	0.70 ± 0.20	0.65 ± 0.19	.3583
Wk 52	1.23 ± 0.33	1.10 ± 0.28	.1894
Skeletal maturity
Baseline (BA/CA)	0.76 ± 0.13	0.77 ± 0.13	.8007
Wk 26 (ΔBA/ΔCA)	0.60 ± 0.71	1.00 ± 0.80	.0840
Week 52 (ΔBA/ΔCA)	0.97 ± 0.50	1.11 ± 0.49	.3056
IGF-1 (ng/mL)
Baseline	108.72 ± 51.82	122.75 ± 52.68	.2364
ΔIGF-1 at Wk 26	162.59 ± 73.76	158.50 ± 116.60	.4246
ΔIGF-1 at Wk 52	180.95 ± 85.84	190.64 ± 87.39	.6896
IGF-1 SDS
Baseline	-0.81 ± 0.83	-0.53 ± 0.67	.1824
Wk 26	1.61 ± 1.43	1.85 ± 2.03	.5508
Wk 52	1.47 ± 1.21	2.14 ± 1.98	.3399
IGFBP-3 (μg/mL)
Baseline	3.21 ± 0.55	3.36 ± 0.66	.4045
ΔIGFBP-3 at Wk 26	1.39 ± 0.70	1.26 ± 0.78	.5046
ΔIGFBP-3 at Wk 52	1.91 ± 0.76	1.60 ± 0.84	.1681